New H1 antihistamines in comparison;Neue H1-antihistaminika im vergleich

Allergologie

Volumn 26, Issue 1, 2003, Pages 24-32

  Borchard, U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Antiallergic antiinflammatory actions; Desloratadine; H1 antihistamines; H1 receptor affinity; Nasal obstruction; Pharmacokinetics; Side effects

Indexed keywords

ANTACID AGENT; ANTIHISTAMINIC AGENT; CETIRIZINE; DESLORATADINE; DEXAMETHASONE; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; MEPYRAMINE; MIZOLASTINE; TERFENADINE;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; DOSE KIDNEY FUNCTION RELATION; DRUG ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; INFLAMMATION; NOSE OBSTRUCTION; REVIEW; SEDATION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 0037278395     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp26024     Document Type: Review

References (24)

1. Agrawal D.K., A. Berro, R.G. Townley: Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation. Allergy 55 (Suppl. 63), 276 (2000).
2. 1 receptors. J. Allergy Clin. Immunol. 105, S385 (2000).
3. Bachert C.: Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 56, 14-20 (2001).
4. Bachert C., B. Lange: Desloratadin: Profil eines moderenen Antihistaminkums. Allergologie 25, 1-10 (2002).
5. Baena-Cagnani C.E.: Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 56, 21-27 (2001).
6. Berthon B., G Taudou, L. Combettes et al.: In vitro inhibition, by loratadine and descarboethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochem. Pharmacol. 47, 789-794 (1994).
7. Clinical Monograph: Cetirizine. ucb Pharma. Adis Int. Lim. (1997).
8. 2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma. J. Allergy Clin. Immunol. 107, S163 (2001).
9. Daly A.F.: Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetirizine and loratadine (abstract). Allergy 56 (Suppl. 68), 20 (2001).
10. 1-receptors. Agents Actions 35, C410-413 (1992).
11. Grewe M., C.A.F.M. Bruijnzeel-Koomen, E. Schöpf, T. Thepaen, A.G. Langeveld-Wildschutz, T. Ruzicka, J. Krutmann: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunology Today 19, 359-361 (1998).
12. Horak F., P. Stübner, R. Ziegelmayer et al.: Decongestant activity of desloratadine versus placebo in allergic rhinitis: Results from three single-dose, placebo-controlled allergen chamber trials. Allergy 56 (Suppl. 68), 79 (2001).
13. Horak F., P Stübner: Decongestant activity of desloratatin in controlled allergen exposure trials. Clin. Drug Invest. 22 (Suppl. 2), 13-20 (2002).
14. Kroegel C., C. Kortsik, W. Luttmann, P. Werner, H. Mathys, J.Chr. Virchow jr.: Prinzipien der therapeutischen Intervention im Rahmen der allergischen Entzündungsreaktion. Allergologie 17, 134-142 (1994).
15. 1-antagonist decarboethoxyloratadine and dexamethasone by human mast and basophilic cell lines. Exp. Dermatol. 4, 272-276 (1995).
16. 2-receptor antagonists. Exp. Dermatol. 9, 118-124 (2000).
17. Lippert U., J. Anthes, S. Eckel on behalf of the Destoratadine Study Group: Binding and antiallergic characteristics of desloratadine. Allergy 56 (Suppl. 68), 112-113 (2001).
18. Nayak A.S., E. Schenkel: Desloratadine reduces nasal congestion in patients with allergic rhinitis. Allergy 56, 1077-1080 (2001).
19. Norman P., A. Dihlmann, X. Rabasseda: Desloratadine: A preclinical and clinical overview. Drugs of Today 37, 215-227 (2001).
20. Prakash A., M. Lamb: Mizolastin. Eine Übersichtsarbeit zum Einsatz bei allergischer Rhinitis und chronischer idiopathischer Urtikaria. BioDrugs 10, 41-63 (1998).
21. Ring J., R. Hein, A. Gauger, E. Bronsky, B. Miller and the Desloratadine Study Group: Once daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Int. J. Dermatol. 40, 1-5 (2001).
22. Slater J.W., D. Zechnich, D.G. Haxby: Second-generation antihistamines. A comparative review. Drugs 57, 31-47 (1999).
23. Van Cauwenberge P. et al.: Consensus statement on the treatment of allergic rhinitis. Allergy 55, 116-134 (2000).
24. Vignola A.M., L. Crampette, M. Mondain et al.: Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 50, 200-203 (1995).